Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Leif William Ellisen, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Leif Ellisen and Aditya Bardia.
Connection Strength

3.333
  1. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. Cancer Discov. 2021 10; 11(10):2436-2445.
    View in: PubMed
    Score: 0.238
  2. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. J Natl Compr Canc Netw. 2021 Mar 24; 1-8.
    View in: PubMed
    Score: 0.232
  3. Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2021 06 15; 27(12):3404-3413.
    View in: PubMed
    Score: 0.229
  4. Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer. Oncotarget. 2021 Jan 19; 12(2):63-65.
    View in: PubMed
    Score: 0.229
  5. Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precis Oncol. 2020 Nov; 4:1246-1262.
    View in: PubMed
    Score: 0.226
  6. Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative. J Natl Compr Canc Netw. 2020 10 15; 1-9.
    View in: PubMed
    Score: 0.225
  7. Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2020 09 15; 26(18):4852-4862.
    View in: PubMed
    Score: 0.220
  8. Novel antibody-drug conjugates for triple negative breast cancer. Ther Adv Med Oncol. 2020; 12:1758835920915980.
    View in: PubMed
    Score: 0.218
  9. FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. Clin Cancer Res. 2019 11 01; 25(21):6443-6451.
    View in: PubMed
    Score: 0.207
  10. Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. NPJ Precis Oncol. 2019; 3:18.
    View in: PubMed
    Score: 0.206
  11. Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. Cancer Discov. 2018 03; 8(3):336-353.
    View in: PubMed
    Score: 0.185
  12. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. Target Oncol. 2017 Dec; 12(6):719-739.
    View in: PubMed
    Score: 0.184
  13. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. J Natl Compr Canc Netw. 2017 10; 15(10):1216-1223.
    View in: PubMed
    Score: 0.182
  14. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1477-1486.
    View in: PubMed
    Score: 0.171
  15. Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. J Clin Oncol. 2015 Nov 01; 33(31):3621-7.
    View in: PubMed
    Score: 0.158
  16. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion. Oncologist. 2021 10; 26(10):818-824.
    View in: PubMed
    Score: 0.059
  17. The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. J Oncol Pharm Pract. 2021 Dec; 27(8):1883-1890.
    View in: PubMed
    Score: 0.056
  18. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol. 2020 04; 38(4):420-425.
    View in: PubMed
    Score: 0.054
  19. PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Ka Inhibitors in Breast Cancer. Cancer Discov. 2020 01; 10(1):72-85.
    View in: PubMed
    Score: 0.052
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.